You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 63 No. 10, October 2006 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (44)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Multiple Sclerosis/ Demyelinating Disease
 •Neuromuscular diseases
 •Neurology, Other
 •Drug Therapy
 •Adverse Effects
 •Immunologic Disorders
 •Immunology, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Altered CD4+/CD8+ T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis

Olaf Stüve, MD, PhD; Christina M. Marra, MD; Amit Bar-Or, MD; Masaaki Niino, MD; Petra D. Cravens, PhD; Sabine Cepok, PhD; Elliot M. Frohman, MD, PhD; J. Theodore Phillips, MD, PhD; Gabriele Arendt, MD; Keith R. Jerome, MD, PhD; Linda Cook, PhD; Francois Grand'Maison, MD; Bernhard Hemmer, MD; Nancy L. Monson, PhD; Michael K. Racke, MD

Arch Neurol. 2006;63:1383-1387.

Background  Treatment with natalizumab, a monoclonal antibody against the adhesion molecule very late activation antigen 4, an {alpha}4beta1 integrin, was recently associated with the development of progressive multifocal leukoencephalopathy, a demyelinating disorder of the central nervous system caused by JC virus infection.

Objective  To test the effect of natalizumab treatment on the CD4+/CD8+ T-cell ratios in cerebrospinal fluid (CSF) and peripheral blood.

Design  Prospective longitudinal study.

Setting  Academic and private multiple sclerosis centers.

Patients  Patients with multiple sclerosis (MS) treated with natalizumab, untreated patients with MS, patients with other neurologic diseases, and human immunodeficiency virus–infected patients.

Main Outcome Measures  CD4+ and CD8+ T cells were enumerated in CSF and peripheral blood. The mean fluorescence intensity of unbound {alpha}4 integrin on peripheral blood CD4+ and CD8+ T cells was analyzed before and after natalizumab therapy.

Results  Natalizumab therapy decreased the CSF CD4+/CD8+ ratio of patients with MS to levels similar to those of human immunodeficiency virus–infected patients. CD4+/CD8+ ratios in peripheral blood in patients with MS progressively decreased with the number of natalizumab doses, but they remained within normal limits. Six months after the cessation of natalizumab therapy, CSF CD4+/CD8+ ratios normalized. The expression of unbound {alpha}4 integrin on peripheral blood T cells decreases with natalizumab therapy and was significantly lower on CD4+ vs CD8+ T cells.

Conclusions  Natalizumab treatment alters the CSF CD4+/CD8+ ratio. Lower expression of unbound {alpha}4 integrin on CD4+ T cells is one possible mechanism. These results may have implications for the observation that some natalizumab-treated patients with MS developed progressive multifocal leukoencephalopathy.


Author Affiliations: Department of Neurology (Drs Stüve, Cravens, Frohman, Monson, and Racke) and Center for Immunology (Drs Monson and Racke), University of Texas Southwestern Medical Center at Dallas; Neurology Section, VA North Texas Health Care System, Medical Service, Dallas (Dr Stüve); Departments of Neurology (Dr Marra) and Laboratory Medicine (Drs Jerome and Cook), University of Washington, Seattle; Department of Neurology and Neurosurgery, Montreal Neurological Institute (Drs Bar-Or and Niino), and Department of Microbiology and Immunology (Dr Bar-Or), McGill University, Montreal, Quebec; Fred Hutchinson Cancer Research Center, Seattle (Drs Jerome and Cook); Department of Neurology, Heinrich Heine University, Düsseldorf, Germany (Drs Stüve, Cepok, Arendt, and Hemmer); Multiple Sclerosis Center at Texas Neurology, Dallas (Dr Phillips); and MS Clinic l'Hôpital Charles LeMoyne, Montreal (Dr Grand'Maison).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Natalizumab and Immune Cells
Henry F. McFarland and Steven Jacobson
Arch Neurol. 2006;63(10):1366-1367.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

OCULAR TOXOPLASMOSIS DURING NATALIZUMAB TREATMENT
Zecca et al.
Neurology 2009;73:1418-1419.
FULL TEXT  

Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
Wenning et al.
NEJM 2009;361:1075-1080.
ABSTRACT | FULL TEXT  

The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-{alpha}4{beta}7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
Soler et al.
J. Pharmacol. Exp. Ther. 2009;330:864-875.
ABSTRACT | FULL TEXT  

Emerging Viral Infections of the Central Nervous System: Part 2
Tyler
Arch Neurol 2009;66:1065-1074.
ABSTRACT | FULL TEXT  

Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells
Kivisakk et al.
Neurology 2009;72:1922-1930.
ABSTRACT | FULL TEXT  

Review: Natalizumab in the treatment of multiple sclerosis
Yaldizli and Putzki
Therapeutic Advances in Neurological Disorders 2009;2:115-128.
ABSTRACT  

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy
Stuve et al.
Neurology 2009;72:396-401.
ABSTRACT | FULL TEXT  

Central Nervous System Immune Surveillance: On Natalizumab, Dendritic Cells, and Dangerous Immune Privilege
Becher
Arch Neurol 2008;65:1566-1567.
FULL TEXT  

Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab
Martin et al.
Arch Neurol 2008;65:1596-1603.
ABSTRACT | FULL TEXT  

Natalizumab: benefit outweighs risk in selected patients with multiple sclerosis
Phillips and Frohman
Therapeutic Advances in Neurological Disorders 2008;1:151-153.
 

Natalizumab: increased vigilance is required in treating patients with multiple sclerosis
Racke and Stuve
Therapeutic Advances in Neurological Disorders 2008;1:155-156.
 

Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis
Krumbholz et al.
Neurology 2008;71:1350-1354.
ABSTRACT | FULL TEXT  

JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?
Verbeeck et al.
Gut 2008;57:1393-1397.
ABSTRACT | FULL TEXT  

Review: Innovative monoclonal antibody therapies in multiple sclerosis
Linker and Kieseier
Therapeutic Advances in Neurological Disorders 2008;1:33-42.
ABSTRACT  

Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab
Bonig et al.
Blood 2008;111:3439-3441.
ABSTRACT | FULL TEXT  

E- and P-Selectin Are Not Required for the Development of Experimental Autoimmune Encephalomyelitis in C57BL/6 and SJL Mice
Doring et al.
J. Immunol. 2007;179:8470-8479.
ABSTRACT | FULL TEXT  

High Incidence of Post-Lumbar Puncture Headaches in Patients With Multiple Sclerosis Treated With Natalizumab: Role of Intrathecal Leukocytes
Stuve et al.
Arch Neurol 2007;64:1055-1056.
FULL TEXT  

Natalizumab for Multiple Sclerosis
Ransohoff
NEJM 2007;356:2622-2629.
FULL TEXT  

Potential Risk of Progressive Multifocal Leukoencephalopathy With Natalizumab Therapy: Possible Interventions
Stuve et al.
Arch Neurol 2007;64:169-176.
ABSTRACT | FULL TEXT  

Natalizumab and immune cells.
McFarland and Jacobson
Arch Neurol 2006;63:1366-1367.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.